Huperzine A

DRUG9 trials

Sponsors

Supernus Pharmaceuticals Inc., National Institute on Aging (NIA), VA Nebraska Western Iowa Health Care System, Hadassah Medical Organization, U.S. Army Medical Research and Development Command

Conditions

Alzheimer DiseaseAlzheimer's DiseaseBioavailabilityBiomarkerBiomarkers, PharmacologicalCognitive Enhancement During ExerciseDementiaDiagnosis

Early Phase 1

Effect of Huperzine A on Cognitive Function and Perception of Effort During Exercise

CompletedNCT03445104

St. Louis UniversityCognitive Enhancement During Exercise

Start: 2018-01-16End: 2018-04-05Updated: 2018-05-31

Phase 2

Huperzine A in Alzheimer's Disease

CompletedNCT00083590

National Institute on Aging (NIA)Alzheimer Disease

Start: 2004-04-30End: 2007-11-30Target: 150Updated: 2008-02-21

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

Shandong Luye Pharmaceutical Co., Ltd.Alzheimer's Disease

Start: 2010-05-31End: 2012-06-30Target: 390Updated: 2011-01-25

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

Shandong Luye Pharmaceutical Co., Ltd.Alzheimer's Disease

Start: 2010-05-31End: 2012-06-30Target: 390Updated: 2011-01-25

Effects of Huperzine A in Treatment of Moderate to Severe TBI

TerminatedNCT01676311

Spaulding Rehabilitation HospitalTraumatic Brain Injury

Start: 2013-12-31End: 2018-08-31Updated: 2019-11-05

RENAISSANCE 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures

Not yet recruitingCTIS2025-520587-18-00

Supernus Pharmaceuticals Inc.Focal Onset Seizures

Target: 45Updated: 2025-11-24

Phase 4

Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia

VA Nebraska Western Iowa Health Care SystemDementia, Schizophrenia

Start: 2009-12-31End: 2011-04-30Target: 15Updated: 2009-11-13

Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging

Shanghai Mental Health CenterBiomarker, Diagnosis, Mild Cognitive Impairment +1

Start: 2019-11-30End: 2025-12-31Target: 300Updated: 2019-04-16

Unknown Phase

Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A

Hadassah Medical OrganizationBioavailability, Healthy

Start: 2010-09-30End: 2011-04-30Target: 8Updated: 2010-06-03

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

CompletedNCT01194336

U.S. Army Medical Research and Development CommandBiomarkers, Pharmacological

Start: 2012-02-29End: 2012-10-31Updated: 2017-05-03